October 11, 2018
Dermavant Sciences to Present Tapinarof Phase 2B Data on Patient-Reported Outcomes for Psoriasis and Atopic Dermatitis at the Fall Clinical Dermatology Conference
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that two abstracts containing Phase 2b data on patient-reported outcomes in psoriasis and atopic dermatitis...
Read Press ReleaseDermavant is a proud sponsor of
Eczema Awareness Month
Dermavant’s
Growing Pipeline
Dermavant is developing investigational drugs to treat atopic dermatitis, acne, hyperhidrosis and other inflammatory skin diseases and medical dermatologic conditions.
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
October 11, 2018
Dermavant Sciences to Present Tapinarof Phase 2B Data on Patient-Reported Outcomes...
Dermavant is a proud sponsor of
Eczema Awareness Month
Patient-Focused
Innovation
The patient is at the heart of everything we do. It is for them that we harness scientific innovations to provide new treatment options for inflammatory skin diseases and medical dermatologic conditions with unmet medical needs.
